Richard Allen, MD
Ophthalmic Plastic and Reconstructive Surgery · Austin, TXNPI 1104827351
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.7%), grants and travel and lodging — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Oyster Point Pharma, Inc. at 47.3% of the total. Reporting peaked in 2024 at $22,250 and has fallen 66.3% since, to $7,502 in 2025. Among ophthalmic plastic and reconstructive surgery clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 30 payments — averaging $1060.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Oyster Point Pharma, Inc.$15K
- Amgen$11K
- Merck$5K
- Rxsight Inc$127
- Johnson & Johnson Surgical Vision, Inc.$83
- Osmotica Pharmaceutical Corp.$19
- plus $13 from 1 others
What the payments were for
- Consulting fees$17,71856%
- Grants$10,00031%
- Travel & lodging$3,23310%
- Food & beverage$8593%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Oyster Point Pharma, Inc. | 7 | $15,038 |
| Amgen(2 entities) | 11 | $11,280 |
| Merck | 8 | $5,250 |
| Rxsight Inc | 1 | $127 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $83 |
| Osmotica Pharmaceutical Corp. | 1 | $19 |
| Bausch & Lomb Americas Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$31,809 in reported general payments places this provider in the 90th percentile of 36 ophthalmic plastic and reconstructive surgery providers in Texas.
See all ophthalmic plastic and reconstructive surgery providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 82 | $1,095 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 15 | $205 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 23 | $76 |
| Tramadol Hcl | 13 | $21 |
Paid to pharmacies, not to this prescriber.
Other ophthalmic plastic and reconstructive surgery in Austin
- Vikram DurairajAustin$379K
- Tanya KhanAustin$10K
- Irina BelinskyAustin$5K
- Sean BlaydonAustin$4K
- Kendall GoodyearAustin$3K
- Tanuj NakraAustin$2K
- Krista StewartAustin$2K
- John ShoreAustin$981
- David GayDripping Springs$93K
- Timothy McCulleyHouston$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.